Hoffman-Censits, J., Tsiatas, M., Chang, P. M., Kim, M., Zagouri, F., Shin, S. J., Kim, S. H., Su, H. Y., Arija, J. Ã. A., Maroto-Rey, J. P., Antonuzzo, L., Maruzzo, M., Tambaro, R., Blais, N., Rottey, S., Gakis, G., Schneider, A., Tyroller, K., Jacob, N., Valderrama, B. P. (2026). Avelumab (Ave) in combination with other anticancer agents as first-line maintenance (1LM) treatment for advanced urothelial carcinoma (aUC): Primary analysis from the JAVELIN Bladder Medley phase 2 trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.739